Corden Connect Shares Innovations, Capabilities

Edition 1 / September 2018
Editorial >> CordenPharma Connects Pharma Supply To Increased Demand In 2018

Edition 1 / September 2018

CordenPharma Executive Leadership - Dr. Riku Rautsola, Chief Executive Officer & President

Author
Dr. Riku Rautsola

CEO & President,
CordenPharma


CordenPharma Connects Pharma Supply To Increased Demand In 2018

Welcome to the first edition of our newsletter Corden Connect! The aim of Corden Connect is to provide you with thought leadership, industry perspectives, and regular updates on recent developments in relation to our five Technology Platforms, which were created to provide you with the full benefit of an Integrated Supply spanning early-phase to commercial manufacturing of APIs, Drug Products, and Pharma Packaging & Logistics.

The first half of 2018 has been exciting for CordenPharma so far – packed with fresh perspectives from a new Leadership Team, important capacity / product expansions, enhanced compliance initiatives, a new CordenPharma Website, and most importantly, our work together to meet your pharma supply requirements and achieve the many important milestones you, our customers, have reached along your path to successful drug development & commercialization.

We started with the successful integration of our new manufacturing facility CordenPharma Boulder (US) into the Highly Potent & Oncology Platform – with this acquisition, CordenPharma has further strengthened its offering in the HPAPI manufacturing space, which complements the existing capabilities at CordenPharma Colorado (US).

Additionally, we completed the construction of a cGMP development facility at CordenPharma Plankstadt (DE) for the development of Highly Potent Oral Solid Dosage Forms, making Plankstadt uniquely positioned to provide development and manufacturing services at any stage and scale for your Highly Potent & Oncology products.

To conclude, I would like to share an important update on our Compliance track record – we are proud to announce the completion of 3 successful FDA inspections in the first half of this year, with no 483 observations reported in CordenPharma Boulder and CordenPharma Plankstadt, and one VAI in CordenPharma Caponago (IT) – a truly remarkable track record reflecting the strong commitment and highest degree of professionalism from our Global Compliance Team and employees in regards to compliance!

Stay Connected! Feel free to reach out directly to the Global Platform Directors or Key Account Managers with any questions or feedback on how we can serve you better in the future.

Here’s to a great fall and continued success in 2018!

Dr. Riku Rautsola
CEO & President, CordenPharma


Subscribe to our Newsletter

Stay up to date with the latest thought leadership articles and news from CordenPharma.